A gynecologic oncologist reviews the current role of immune checkpoint inhibition across locally advanced and recurrent cervical cancer settings, including KEYNOTE-A18 survival data, key regulatory distinctions, and unanswered sequencing questions.

A jury assigned 35% of liability to a second-opinion physician and health center after a patient underwent an unnecessary hysterectomy based on a contaminated biopsy specimen, finding that discordant pathology results were not reconciled and informed consent was not obtained.

An ESMO express update to epithelial ovarian cancer guidelines added rucaparib and mirvetuximab soravtansine as treatment options, but expert commentary and two subsequent FDA approvals have raised questions about the update’s current clinical applicability.

Hematopoietic loss of the X chromosome in peripheral blood was associated with more than twofold the odds of failing to conceive naturally in a Japanese multicenter case-control study, with no corresponding association found in women undergoing ART.

Following a 14-year international consensus effort involving 56 professional and patient organizations, polycystic ovary syndrome is being renamed polyendocrine metabolic ovarian syndrome, with full guideline incorporation expected by 2028.

Synthetic DNA molecules known as polypurine reverse Hoogsteen hairpins reduced PCSK9 expression and lowered LDL cholesterol by approximately 50% in preclinical models, representing an early-stage gene-targeted approach distinct from existing monoclonal antibody and RNA interference strategies.